<DOC>
	<DOCNO>NCT00782717</DOCNO>
	<brief_summary>The purpose study determine whether nepafenac safe effective reduce incidence macular edema follow cataract surgery diabetic retinopathy patient .</brief_summary>
	<brief_title>A Clinical Safety Efficacy Comparison NEVANAC 0.1 % Vehicle After Cataract Surgery Diabetic Retinopathy Patients</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Nepafenac</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients nonproliferative diabetic retinopathy ( mild , moderate severe ) plan cataract extraction phacoemulsification . Other protocoldefined inclusion criterion may apply . Central subfiled macular thickness great equal 250 micron CME either eye . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>diabetic retinopathy</keyword>
	<keyword>cystoid macular edema ;</keyword>
</DOC>